Ibrutinib to Treat Chronic Graft Versus Host Disease
David Miklos, MD
David Miklos, MD of Stanford University talks about the use of ibrutinib in chronic graft versus host disease.
Miklos D, Cutler CS, Arora M, et al. Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids. Presented at the 58th Annual ASH Meeting and Exposition; San Diego, CA; December 3-6, 2016.